# Study of VTD in Waldenstrom's Macroglobulinemia

> **NCT03335098** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia
- Lymphoplasmacytic Lymphoma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT03335098
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-21
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2017-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335098, "Study of VTD in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03335098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*